Researchers at the Johns Hopkins University School of Medicine say that how fast the amount of PSA (prostate-specific antigen) in a man's blood increases, or PSA velocity (PSAV), is an accurate gauge of tumor aggression and danger, even when PSA levels
Outlandish portions. Sky-high salt content. Employees who don’t wash their hands. There are hazards aplenty at your favorite restaurant, but now health officials in New York and Chicago believe that they have cornered a real killer in the kitchen
When interpreting prostate cancer screening test results, physicians should consider the impact of a patient's body mass index, regardless of race, according to a new study.
Mary Wittenberg, the 44-year-old president of New York Road Runners, is a fast, strong and experienced runner. But she races best, she says, when she runs just behind Witold Bialokur. He can run 10 kilometers, or 6.2 miles, in less than 44 minutes and
Bayer A.G.’s limp excuse for withholding data suggesting that a heart-surgery drug is dangerous won’t wash. The failure by the German pharmaceutical giant to inform the Food and Drug Administration of the disquieting results of a large obse
In the first randomized trial of its kind, Tadalafil, a drug typically prescribed for erectile dysfunction in men, has been proven to increase the sexual function of prostate cancer survivors
Prostate cancer researchers at Sydney's Garvan Institute, supported by the Cancer Institute NSW, have found a new marker for identifying aggressive prostate cancers.
Every patient in the cardiac care unit at the San Filippo Neri Hospital who survives a heart attack goes home with a prescription for purified fish oil, or omega-3 fatty acids.
A new McGill University study that used thermal imaging technology for the first time ever to measure sexual arousal rates has turned the conventional wisdom that women become aroused more slowly than men on its head.
In the first randomized trial of its kind, Tadalafil, a drug typically prescribed for erectile dysfunction in men, has been proven to increase the sexual function of prostate cancer survivors, according to a study released today from the International
Researchers at Baylor College of Medicine (BCM) are hoping a new gene therapy that takes a gene called RTVP-1 directly into the prostate tumor will prove effective in preventing recurrence of the disease.
A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the Sept. 20 Journal of Clinical Oncology.
A team of researchers at Purdue University has found a protein in the blood that may prove to be more reliable than the standard prostate specific antigen (PSA) test in measuring the extent of prostate cancer.
